Characterisation of oxazepam degradation products by high-performance liquid chromatography/electrospray ionisation mass spectrometry and electrospray ionisation quadrupole time-of-flight tandem mass spectrometry

Rapid Communications in Mass Spectrometry

Volumn 24, Issue 5, 2010, Pages 651-658

  Smyth, Thomas J P ^a   Robledo, Virginia Rodríguez ^b   Franklin Smyth, W ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORINE COMPOUNDS; DEGRADATION; DRUG PRODUCTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHASE SEPARATION; SODIUM HYDROXIDE;

CONTROLLED DEGRADATION; DEGRADATION MIXTURES; DEGRADATION PRODUCTS; FRAGMENTATIONS PATTERN; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY-ELECTROSPRAY IONIZATION-MASS SPECTROMETRIES; NEUTRALISATION; OXAZEPAM; QUADRUPOLE TIME-OF-FLIGHT TANDEM MASS SPECTROMETRIES; SOLID-PHASE EXTRACTION;

ELECTROSPRAY IONIZATION;

EID: 77049111555     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.4433     Document Type: Article

References (33)

1. Moller HJ. J. Clin. Psychopharmacol. 1999; 19: 2S.
2. Lader MH. Eur. Neuropsychopharmacol. 1999; 9: 399.
3. Ashton H. Drugs 1994; 48: 25.
4. Argyropoulos SV, Nutt DJ. Eur. Neuropsychopharmacol. 1999; 9: 407.
5. Pelissolo A. Encéphale 1996; 22: 187.
6. Garretty DJ, Wolff K, Hay AW, Raistrick D. Ann. Clin. Biochem. 1997; 34: 68.
7. Verwey B, Eling P, Wientjes H, Zitman FG. J. Clin. Psychiatry 2000; 61: 456.
8. Goodman & Gilman's, The Pharmacological Basis of Therapeutics, (10th edn). McGraw Hill Medical Publishing Division: London, 2001; 337-366.
9. Skerritt JH, Johnston GA. Eur. J. Pharmacol. 1983; 89: 193.
10. Oelschlager H. Schweiz Rundsch. Med. Prax. 1989; 78: 766.
11. European Pharmacopoeia, (6th edn). Council of Europe: Strasbourg, 2007.
12. United States Pharmacopoeia and National-Formulation, USP-NF, United States Pharmacopoeia Convention, (August) 2009; 3 volumes.
13. British Pharmacopoeia 2009. Her Majesty's Stationary Office: London, 2009.
14. The United States Pharmacopeia, (20th revision). United States Pharmacopeia Convention: Rockville, MD, 1980; 570.
15. Fazzari FR, Riggleman OH. J. Pharm. Sci. 1969; 58: 1530.
16. Brooks MA, Bel Druno JJ, DeSilva JAF, Hackman MR. Anal. Chim. Acta 1975; 74: 367.
17. Umezawa H, Lee XP, Arima Y, Hasegawa C, Marumo A, Kumazawa T, Sato K. Rapid Commun. Mass Spectrom. 2008; 22: 2333.
18. Lee XP, Kumazawa T, Fujishiro M, Hasegawa C, Marumo A, Shoji Y, Arinobu T, Seno H, Sato K. J. Pharmaceut. Biomed. Anal. 2006; 41: 64.
19. Fujimaki K, Lee X-P, Kumazawa T, Sato J, Sato K. Forensic Toxicol. 2006; 24: 8.
20. Umezawa H, Lee X-P, Arima Y, Hasegawa C, Izawa H, Kumazawa T, Sato K. Biomed. Chromatogr. 2008; 22: 702.
21. Kauppila TJ, Talaty N, Kuuranne T, Kotiaho T, Kostiainen R, Cooks RG. Analyst 2007; 132: 868.
22. Kinani S, Bouchonnet S, Milan N, Ricordel I. J. Chromatogr. A 2007; 1141: 221.
23. Laloup M, Fernandez MMR, Wood M, Maes V, de Boeck G, Vanbeckevoort Y, Samyn N. Anal. Bioanal. Chem. 2007; 388: 1545.
24. Hegstad S, Øiestad EL, Johansen U, Christophersen AS. J. Anal. Toxicol. 2006; 30: 31.
25. Sadee W, Van der Kleijn E. J. Pharm. Sci. 1971; 60: 135.
26. Forgione A, Martelli P, Marcucci F, Fanelli R, Mussini E, Jommi GC. J. Chromatogr. 1971; 59: 163.
27. Joice JR, Bal TS, Ardrey RE, Stevens HM, Moffat AC. Biomed. Mass Spectrom. 1984; 11: 284.
28. Bell SC, Childress SJ. J. Org. Chem. 1964; 29: 506.
29. DeSilva JAF, Koechlin BA, Bader G. J. Pharm. Sci. 1966; 55: 692.
30. DeSilva JAF, Schwartz MA, Stefanovic V, Kaplan J, D'Arconte L. Anal. Chem. 1964; 36: 2099.
31. Han WW, Yakatan GJ, Maness DD. J. Pharm. Sci. 1977; 66: 573.
32. Bell SC, Childress SJ. J. Org. Chem. 1962; 27: 1691.
33. Sisenwine SF, Tio CO, Shrader SK, Ruelius HW. Arzneim-Forsch. 1972; 22: 682.